Dialogue Health Technologies Inc.
DLHTF · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.43 | 0.41 | 0.26 |
| FCF Yield | -1.22% | -3.27% | 1.66% | -0.70% |
| EV / EBITDA | -38.90 | -83.95 | -68.02 | -24.16 |
| Quality | ||||
| ROIC | -5.76% | -3.22% | -3.34% | -5.91% |
| Gross Margin | 59.69% | 57.38% | 54.66% | 52.17% |
| Cash Conversion Ratio | 0.37 | 2.27 | -0.69 | 0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.67% | 24.26% | 34.51% | 56.85% |
| Free Cash Flow Growth | 63.24% | -296.96% | 334.11% | 87.35% |
| Safety | ||||
| Net Debt / EBITDA | 6.93 | 15.92 | 33.01 | 10.17 |
| Interest Coverage | -213.52 | -116.70 | -95.69 | -250.74 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -79.08 | -44.83 | 50.19 | -41.83 |